Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-α release from human alveolar macrophages

European Respiratory Journal

Volumn 29, Issue 5, 2007, Pages 986-994

  Ratcliffe, Marianne J ^a   Walding, A ^a   Shelton, P A ^a   Flaherty, A ^a   Dougall, I G ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Alveolar; Cytokine; Human; Macrophage; Prostaglandin E2

Indexed keywords

LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID; PROSTANOID RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; EP4 RECEPTOR; PROSTAGLANDIN E RECEPTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LUNG ALVEOLUS MACROPHAGE; LUNG CARCINOMA; LUNG DISEASE; LUNG RESECTION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VOLUNTEER; ANALYSIS OF VARIANCE; BIOSYNTHESIS; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; PHYSIOLOGY; STATISTICAL MODEL;

ANALYSIS OF VARIANCE; COMPUTER SIMULATION; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; LIPOPOLYSACCHARIDES; LOGISTIC MODELS; MACROPHAGES, ALVEOLAR; RECEPTORS, PROSTAGLANDIN E; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248155663     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00131606     Document Type: Article

References (30)

1. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 29S-32S.
2. Coleman RA, Smith WL, Narumiya S. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205-229.
3. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000; 1483: 285-293.
4. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya. S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997; 122: 217-224.
5. Schultz RM, Pavlidis NA, Stylos WA, Chirigos MA. Regulation of macrophage tumoricidal function: a role for prostaglandins of the E series. Science 1978; 202: 320-321.
6. Schultz RM, Pavlidis NA, Stoychkov JN, Chirigos MA. Prevention of macrophage tumoricidal activity by agents known to increase cellular cyclic AMP. Cell Immunol 1979; 42: 71-78.
7. Rossi AG, McCutcheon JC, Roy N, Chilvers ER, Haslett C, Dransfield I. Regulation of macrophage phagocytosis of apoptotic cells by cAMP. J Immunol 1998; 160: 3562-3568.
8. Aronoff DM, Canetti C, Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol 2004; 173: 559-565.
9. Christman JW, Christman BW, Shepherd VL, Rinaldo JE. Regulation of alveolar macrophage production of chemoattractants by leukotriene B4 and prostaglandin E2. Am J Respir Cell Mol Biol 1991; 5: 297-304.
10. Ozaki T, Moriguchi H, Nakamura Y, Kamei T, Yasuoka S, Ogura T. Regulatory effect of prostaglandin E2 on fibronectin release from human alveolar macrophages. Am Rev Respir Dis 1990; 141: 965-969.
11. Akaogi J, Yamada H, Kuroda Y, Nacionales DC, Reeves WH, Satoh M. Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. J Leukoc Biol 2004; 76: 227-236.
12. Treffkorn L, Scheibe R, Maruyama T, Dieter P. PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostaglandins Other Lipid Mediat 2004; 74: 113-123.
13. Renz H, Gong JH, Schmidt A, Nain M, Gemsa D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol 1988; 141: 2388-2393.
14. Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med 1994; 180: 2365-2370.
15. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr, Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002; 277: 44147-44154.
16. Monick M, Glazier J, Hunninghake GW. Human alveolar macrophages suppress interleukin-1 (IL-1) activity via the secretion of prostaglandin E2. Am Rev Respir Dis 1987; 135: 72-77.
17. Standiford TJ, Kunkel S, Rolfe MW, Evanoff HL, Allen RM, Strieter RM. Regulation of human alveolar macrophage-and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone. Am J Respir Cell Mol Biol 1992; 6: 75-81.
18. Rowe J, Finlay-Jones JJ, Nicholas TE, Bowden J, Morton S, Hart PH. Inability of histamine to regulate TNF-alpha production by human alveolar macrophages. Am J Respir Cell Molecular Biol 1997; 17: 218-226.
19. Kitamura T, Itoh M, Noda T, et al. Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci 2003; 94: 618-621.
20. Trist DG, Leff P. Quantification of H2-agonism by clonidine and dimaprit in an adenylate cyclase assay. Agents Actions 1985; 16: 222-226.
21. Furchgott RF. Adrenergic and dopaminergic peripheral receptors. Proceedings of the 4th Meeting on Adrenergic Mechanisms. Porto, Portugal, 1981; pp. 10-29.
22. Furchgott RF. The use of B-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agpmost complexes. Adv Drug Res 1966; 3: 21-55.
23. Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother 1956; 11: 379-393.
24. Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, Sheldrick RLG. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 1994; 47: 151-168.
25. Regan JW, Bailey TJ, Pepperl DJ, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 1994; 46: 213-220.
26. Stone M, Angus JA. Developments of computer-based estimation of pA2 values and associated analysis. J Pharmacol Exp Ther 1978; 207: 705-718.
27. Blaschke V, Jungermann K, Puschel GP. Exclusive expression of the Gs-linked prostaglandin E2 receptor subtype 4 mRNA in human mononuclear Jurkat and KM-3 cells and coexpression of subtype 4 and 2 mRNA in U-937 cells. FEBS Lett 1996; 394: 39-43.
28. Beusenberg FD, Hoogsteden HC, Bonta IL, van Amsterdam JGC. Cyclic AMP enhancing drugs modulate eicosanoid release from human alveolar macrophages. Life Sci 1994; 54: 1269-1274.
29. Nishigaki N, Negishi M, Ichikawa A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol Pharmacol 1996; 50: 1031-1037.
30. Meja KK, Barnes PJ, Giembycz MA. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 1997; 122: 149-157.